{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:47:13Z","timestamp":1785527233080,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","award":["E63C25000210002"],"award-info":[{"award-number":["E63C25000210002"]}],"id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022YCMF4"],"award-info":[{"award-number":["2022YCMF4"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41375-026-03037-7","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:10:23Z","timestamp":1782465023000},"page":"1604-1607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From data to evidence: why administrative databases alone cannot measure real-world effectiveness in rare diseases \u2013 the case of chronic myeloid leukaemia"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3357-5655","authenticated-orcid":false,"given":"Sara","family":"Mucherino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Menditto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8209-8878","authenticated-orcid":false,"given":"Valentina","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"3037_CR1","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1038\/s41375-025-02751-y","volume":"39","author":"RP Gale","year":"2025","unstructured":"Gale RP, Hochhaus A. Are real world data real world data? Leukemia. 2025;39:2311\u20132.","journal-title":"Leukemia"},{"key":"3037_CR2","unstructured":"U.S. Food and Drug Administration. Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products: guidance for industry. Silver Spring, MD: FDA; 2023. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug. Accessed 1st april 2026."},{"key":"3037_CR3","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMp2200089","volume":"386","author":"J Concato","year":"2022","unstructured":"Concato J, Corrigan-Curay J. Real-world evidence - where are we now? N Engl J Med. 2022;386:1680\u20132.","journal-title":"N Engl J Med"},{"key":"3037_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1080\/09332480.2019.1579578","volume":"32","author":"MA Hern\u00e1n","year":"2019","unstructured":"Hern\u00e1n MA, Hsu J, Healy B. A second chance to get causal inference right: a classification of data science tasks. CHANCE. 2019;32:42\u201349.","journal-title":"CHANCE"},{"key":"3037_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/pds.5490","volume":"31","author":"L Rasmussen","year":"2022","unstructured":"Rasmussen L, Wettermark B, Steinke D, Potteg\u00e5rd A. Core concepts in pharmacoepidemiology: measures of drug utilization based on individual-level drug dispensing data. Pharmacoepidemiol Drug Saf. 2022;31:1015\u201326.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3037_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100914","volume":"54","author":"F Passamonti","year":"2022","unstructured":"Passamonti F, Corrao G, Castellani G, Mora B, Maggioni G, Gale RP, et al. The future of research in hematology: integration of conventional studies with real-world data and artificial intelligence. Blood Rev. 2022;54:100914.","journal-title":"Blood Rev"},{"key":"3037_CR7","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797\u2013813.","journal-title":"Leukemia"},{"key":"3037_CR8","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","volume":"37","author":"NCP Cross","year":"2023","unstructured":"Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023;37:2150\u201367.","journal-title":"Leukemia"},{"key":"3037_CR9","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","volume":"94","author":"M H\u00f6glund","year":"2015","unstructured":"H\u00f6glund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94:S241\u20137.","journal-title":"Ann Hematol"},{"key":"3037_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.675609","volume":"11","author":"M Pajiep","year":"2021","unstructured":"Pajiep M, Conte C, Huguet F, Gauthier M, Despas F, Lapeyre-Mestre M. Patterns of tyrosine kinase inhibitor utilization in newly treated patients with chronic myeloid leukemia: an exhaustive population-based study in France. Front Oncol. 2021;11:675609.","journal-title":"Front Oncol"},{"key":"3037_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2025.2478344","volume":"30","author":"T Toptas","year":"2025","unstructured":"Toptas T, Demirtas D, Yanik AM, Candan O, Arikan F, Salim S, et al. Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia. Hematology. 2025;30:2478344.","journal-title":"Hematology"},{"key":"3037_CR12","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00277-023-05159-9","volume":"102","author":"L Luciano","year":"2023","unstructured":"Luciano L, Latagliata R, Gugliotta G, Annunziata M, Tiribelli M, Martino B, et al. Efficacy and safety of nilotinib as frontline treatment in elderly (>\u200965 years) chronic myeloid leukemia patients outside clinical trials. Ann Hematol. 2023;102:1375\u201382.","journal-title":"Ann Hematol"},{"key":"3037_CR13","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-021-01260-y","volume":"35","author":"TP Hughes","year":"2021","unstructured":"Hughes TP, Clementino NCD, Fominykh M, Lipton JH, Turkina AG, Moiraghi EB, et al. Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. Leukemia. 2021;35:1631\u201342.","journal-title":"Leukemia"},{"key":"3037_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2024.101536","volume":"37","author":"F Passamonti","year":"2024","unstructured":"Passamonti F, Corrao G, Castellani G, Mora B, Maggioni G, Della Porta MG, et al. Using real-world evidence in haematology. Best Pract Res Clin Haematol. 2024;37:101536.","journal-title":"Best Pract Res Clin Haematol"},{"key":"3037_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/03007995.2025.2482665","volume":"41","author":"C Nguyen","year":"2025","unstructured":"Nguyen C, Zheng H, Grabner M, Barron J, Dixon RW, Cziraky M, et al. Integration of administrative claims and clinical data to advance real-world evidence generation in oncology. Curr Med Res Opin. 2025;41:671\u201381.","journal-title":"Curr Med Res Opin"},{"key":"3037_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2024.101354","volume":"41","author":"MJ Eckrote","year":"2024","unstructured":"Eckrote MJ, Nielson CM, Lu M, Alexander T, Gupta RS, Low KW, et al. Linking clinical trial participants to their U.S. real-world data through tokenization: a practical guide. Contemp Clin Trials Commun. 2024;41:101354.","journal-title":"Contemp Clin Trials Commun"},{"key":"3037_CR17","first-page":"2998","volume":"49","author":"PG Casali","year":"2013","unstructured":"Casali PG, Bruzzi P, Bogaerts J, Blay JY. Rare Cancers Europe (RCE) Consensus Panel. Rare cancers: towards a coordinated European regulatory approach. Eur J Cancer. 2013;49:2998\u20133006.","journal-title":"Eur J Cancer"},{"key":"3037_CR18","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1182\/bloodadvances.2019000865","volume":"3","author":"M Baccarani","year":"2019","unstructured":"Baccarani M, Abruzzese E, Accurso V, Albano F, Annunziata M, Barulli S, et al. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. Blood Adv. 2019;3:4280\u201390.","journal-title":"Blood Adv"},{"key":"3037_CR19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"3037_CR20","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.3390\/cancers17132148","volume":"17","author":"G Bourne","year":"2025","unstructured":"Bourne G, Diebold K, Bascug G, Knapp J, Espinoza-Gutarra M, Vachhani P, et al. Real-world evidence of treatment-free remission strategies and outcomes in chronic myeloid leukemia. Cancers. 2025;17:2148.","journal-title":"Cancers"},{"key":"3037_CR21","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/leu.2015.152","volume":"29","author":"F Castagnetti","year":"2015","unstructured":"Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015;29:1823\u201331.","journal-title":"Leukemia"},{"key":"3037_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2025.2534196","volume":"30","author":"T Devos","year":"2025","unstructured":"Devos T, Deeren D, Theunissen K, Selleslag D, Bailly B, Havelange V, et al. Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib - final 6-year results from a Belgian registry. Hematology. 2025;30:2534196.","journal-title":"Hematology"},{"key":"3037_CR23","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3324\/haematol.2017.174953","volume":"102","author":"IGP Geelen","year":"2017","unstructured":"Geelen IGP, Thielen N, Janssen JJWM, Hoogendoorn M, Roosma TJA, Willemsen SP, et al. Treatment outcome in a population-based, \u2018real-world\u2019 cohort of patients with chronic myeloid leukemia. Haematologica. 2017;102:1842\u20139.","journal-title":"Haematologica"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03037-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03037-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03037-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:10:22Z","timestamp":1785521422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03037-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3037"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03037-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}